The Mason, Ohio-based cardiovascular device company posted losses of -$6.9 million, or -21¢ per share, on sales of $45.2 million for the three months ended June 30, paring its losses by -16.1% on sales growth of 14.0% compared with Q2 2016.
Analysts on Wall Street were looking for losses per share of -21¢ on sales of $43.3 million.
“We are executing on our strategy to deliver solid, balanced, results across our business while progressing forward our clinical trials and strategic initiatives,” president & CEO Mike Carrel said in prepared remarks. “We are also continuing to strengthen our leadership team and look forward to sustained momentum across our business throughout 2017.”
AtriCure said it still expects to post losses of -94¢ to $1.04 per share this year, but raised the low end of its 2017 sales guidance to $177 million to $178 million, compared with $175 million to $178 million previously.
ATRC shares were up 6.4% to $24.14 in mid-morning trading today.